Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders

Bibliography

• Jonsson-Berling BM, Ohlsson K, Rosengren M. Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. Biol Chem Hoppe Seyler 1989;370:1157-61
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Aibiki M, Hanaoka K. The effect of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymorphonuclear granulocyte elastase. Anesth Analg 1996;82:108-12
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Kosuzume H, Ashida Y, Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis. Dig Dis Sci 1984;29:26-32
   PubMed Web of Science ®Google Scholar
• Okabe H, Irita K, Kurosawa K, Increase in the plasma concentration of reduced glutathione observed in rats with liver damage induced by lipopolysaccharide/D-galactosamine: effects of ulinastatin, a urinary trypsin inhibitor. Circ Shock 1993;41:268-72
   PubMedGoogle Scholar
• Salier JP, Rouet P, Raguenez G, Daveau M. The inter-alpha-inhibitor family: from structure to regulation. Biochem J 1996;315:1-9
   PubMed Web of Science ®Google Scholar
• Sjoberg EM, Fries E. Biosynthesis of bikunin (urinary trypsin inhibitor) in rat hepatocytes. Arch Biochem Biophys 1992;295:217-22
   PubMed Web of Science ®Google Scholar
• Thogersen IB, Enghild JJ. Biosynthesis of bikunin proteins in the human carcinoma cell line HepG2 and in primary human hepatocytes. Polypeptide assembly by glycosaminoglycan. J Biol Chem 1995;270:18700-9
   PubMed Web of Science ®Google Scholar
• Heron A, Bourguignon J, Calle A, Post-translational processing of the inter-alpha-trypsin inhibitor in the human hepatoma HepG2 cell line. Biochem J 1994;302:573-80
   PubMed Web of Science ®Google Scholar
• Heron A, Bourguignon J, Diarra-Mehrpour M, Involvement of the three inter-alpha-trypsin inhibitor (ITI) heavy chains in each member of the serum ITI family. FEBS Lett 1995;374:195-8
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Suzuki K, Hiho T, Protective effects of urinary trypsin inhibitor in experimental shock. Japan J Pharmacol 1985;39:137-44
   PubMedGoogle Scholar
• Albani D, Balduyck M, Mizon C, Mizon J. Inter-alpha-inhibitor as marker for neutrophil proteinase activity: an in vitro investigation. J Lab Clin Med 1997;130:339-47
   PubMedGoogle Scholar
• Balduyck M, Albani D, Jourdain M, Inflammation-induced systemic proteolysis of inter-alpha-inhibitor in plasma from patients with sepsis. J Lab Clin Med 2000;135:188-98
   PubMedGoogle Scholar
• Mizon C, Piva F, Queyrel V, Urinary bikunin determination provides insight into proteinase/proteinase inhibitor imbalance in patients with inflammatory diseases. Clin Chem Lab Med 2002;40:579-86
   PubMed Web of Science ®Google Scholar
• Hirose J, Ozawa T, Miura T, Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 1998;21:651-6
   PubMed Web of Science ®Google Scholar
• Balduyck M, Mizon J. Inter-alpha-trypsin inhibitor and its plasma and urine derivatives. Ann Biol Clin (Paris) 1991;49:273-81
   PubMed Web of Science ®Google Scholar
• Pugia MJ, Valdes R Jr, Jortani SA. Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement. Adv Clin Chem 2007;44:223-45
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Suzuki M, Tanaka Y, Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem 2001;276:2015-22
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Gotoh J, Terao T. Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells. Eur J Cell Biol 1996;71:380-6
   PubMed Web of Science ®Google Scholar
• Tsujino T, Komatsu Y, Isayama H, Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005;3:376-83
   PubMed Web of Science ®Google Scholar
• Endo S, Inada K, Yamashita H, The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and interleukin 8. Res. Commun Chem Pathol Pharmacol 1993;82:27-34
   PubMedGoogle Scholar
• Nakatani K, Takeshita S, Tsujimoto H, Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001;69:241-7
   PubMed Web of Science ®Google Scholar
• Aosasa S, Ono S, Mochizuki H, Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001;15:101-5
   PubMed Web of Science ®Google Scholar
• Endo S, Inada K, Taki K, Inhibitory effects of ulinastatin on the production of cytokines: implications for the prevention of septicemic shock. Clin Ther 1990;12:323-6
   PubMed Web of Science ®Google Scholar
• Maehara K, Kanayama N, Halim A, Down-regulation of interleukin-8 gene expression in HL60 cell line by human Kunitz-type trypsin inhibitor. Biochem Biophys Res Commun 1995;206:927-34
   PubMed Web of Science ®Google Scholar
• Nakamura H, Abe S, Shibata Y, Inhibition of neutrophil elastase-induced interleukin-8 gene expression by urinary trypsin inhibitor in human bronchial epithelial cells. Int Arch Allergy Immunol 1997;112:157-62
   PubMed Web of Science ®Google Scholar
• Matsuzaki H, Kobayashi H, Yagyu T, Bikunin inhibits lipopolysaccharide-induced tumor necrosis factor alpha induction in macrophages. Clin Diagn Lab Immunol 2004;11:1140-7
   PubMedGoogle Scholar
• Aibiki M, Cook JA. Ulinastatin, a human trypsin inhibitor, inhibits endotoxin-induced thromboxane B2 production in human monocytes. Crit Care Med 1997;25:430-4
   PubMed Web of Science ®Google Scholar
• Cook JA, Geisel J, Temple GE, Endotoxin activation of eicosanoid production by macrophages. In: Schlag F, Redl H, editors, Pathophysiology of shock, sepsis and organ failure. Springer-Verlag, Heidelberg, Germany; 1993. p. 518-30
   Google Scholar
• Molor-Erdene P, Okajima K, Isobe H, Urinary trypsin inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-alpha production through inhibition of Egr-1 expression. Am J Physiol Heart Circ Physiol 2005;288:H1265-71
   PubMed Web of Science ®Google Scholar
• Okano S, Tagawa M, Urakawa N, Ogawa R. A therapeutic effect of ulinastatin on endotoxin-induced shock in dogs-comparison with methylprednisolone. J Vet Med Sci 1994;56:645-9
   PubMed Web of Science ®Google Scholar
• Tani T, Aoki H, Yoshioka T, Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomized, controlled trial. Crit Care Med 1993;21:925-30
   PubMed Web of Science ®Google Scholar
• Wakahara K, Kobayashi H, Yagyu T, Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor- alpha and interleukin-1 beta in macrophages. J Infect Dis 2005;191:930-8
   PubMed Web of Science ®Google Scholar
• Molor-Erdene P, Okajima K, Isobe H, Inhibition of lipopolysaccharide-induced tissue factor expression in monocytes by urinary trypsin inhibitor in vitro and in vivo. Thromb Haemost 2005;94:136-45
   PubMed Web of Science ®Google Scholar
• Masuda T, Sato K, Noda C, Protective effect of urinary trypsin inhibitor on myocardial mitochondria during hemorrhagic shock and reperfusion. Crit Care Med 2003;31:1987-92
   PubMed Web of Science ®Google Scholar
• Aihara T, Shiraishi M, Hiroyasu S, Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by downregulating TNF-alpha in the liver. Transplant Proc 1998;30:3732-4
   PubMed Web of Science ®Google Scholar
• Nakahama H, Obata K, Sugita M. Ulinastatin ameliorates acute ischemic renal injury in rats. Ren Fail 1996;18:893-8
   PubMed Web of Science ®Google Scholar
• Cao ZL, Okazaki Y, Naito K, Ulinastatin attenuates reperfusion injury in the isolated blood-perfused rabbit heart. Ann Thorac Surg 2000;69:1121-6
   PubMed Web of Science ®Google Scholar
• Binns OA, DeLima NF, Buchanan SA, Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. J Thorac Cardiovasc Surg 1996;112:607-13
   PubMed Web of Science ®Google Scholar
• Okuhama Y, Shiraishi M, Higa T, Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res 1999;82:34-42
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Ohshiro H, Nagao Y, Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res 2000;94:107-15
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006;34:1351-7
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Yokoyama T, Yamashita K. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery. J Anesth 2006;20:179-82
   PubMedGoogle Scholar
• Kurosawa S, Kanaya N, Fujimura N, Effects of ulinastatin on pulmonary artery pressure during abdominal aortic aneurysmectomy. J Clin Anesth 2006;18:18-23
   PubMed Web of Science ®Google Scholar
• Yano T, Anraku S, Nakayama R, Ushijima K. Neuroprotective effect of urinary trypsin inhibitor against focal cerebral ischemia-reperfusion injury in rats. Anesthesiology 2003;98:465-73
   PubMed Web of Science ®Google Scholar
• Umeki S, Tsukiyama K, Okimoto N, Soejima R. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity. Am J Med Sci 1989;298:221-6
   PubMed Web of Science ®Google Scholar
• Ishigami M, Eguchi M, Yabuki S. Beneficial effects of the urinary trypsin inhibitor urinastatin on renal insults induced by gentamicin and mercuric chloride (HgCl2) poisoning. Nephron 1991;58:300-5
   PubMedGoogle Scholar
• Kobayashi H, Ohi H, Terao T. Prevention by urinastatin of cis-diamminedichloroplatinum-induced nephrotoxicity in rabbits: comparison of urinary enzyme excretions and morphological alterations by electron microscopy. Asia Oceania J Obstet Gynaecol 1991;17:277-88
   PubMedGoogle Scholar
• Yamasaki F, Ishibashi M, Nakakuki M, Protective action of ulinastatin against cisplatin nephrotoxicity in mice and its effect on the lysosomal fragility. Nephron 1996;74:158-67
   PubMed Web of Science ®Google Scholar
• Ishibashi M, Yamasaki F, Nakakuki M, Cytoprotective effect of ulinastatin on LLC-PK1 cells treated with antimycin A, gentamicin, and cisplatin. Nephron 1997;76:300-6
   PubMedGoogle Scholar
• Koizumi R, Kanai H, Maezawa A, Therapeutic effects of ulinastatin on experimental crescentic glomerulonephritis in rats. Nephron 2000;84:347-53
   PubMedGoogle Scholar
• Huang Y, Xie K, Zhang J, Prospective clinical and experimental studies on the cardioprotective effect of ulinastatin following severe burns. Burns 2008;34:674-80
   PubMed Web of Science ®Google Scholar
• Tsujimura S, Saito K, Nakayamada S, Tanaka Y. Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. Mod Rheumatol 2005;15:374-80
   PubMedGoogle Scholar
• Komori M, Takada K, Tomizawa Y, Urinary trypsin inhibitor improves peripheral microcirculation and bronchospasm associated with systemic anaphylaxis in rabbits in vivo. Shock 2003;20:189-94
   PubMed Web of Science ®Google Scholar
• Inamo Y, Okubo T, Wada M, Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol 2002;127:89-94
   PubMed Web of Science ®Google Scholar
• Harashima S, Tsukamoto H, Nishizaka H, Successful treatment of invasive pulmonary aspergillosis by transbronchial injection of urinary trypsin inhibitor and amphotericin B. Acta Haematol 2003;109:156-7
   PubMed Web of Science ®Google Scholar
• Sato A, Kuwabara Y, Shinoda N, Use of low dose dopamine, gabexate mesilate and ulinastatin reduces the water balance and pulmonary complication in thoracic esophagectomy patients. Dis Esophagus 2005;18:151-4
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Suzuki M, Tanaka Y, A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade. J Biol Chem 2003;278:7790-9
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Yagyu T, Inagaki K, Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer. Cancer 2004;100:869-77
   PubMed Web of Science ®Google Scholar
• Suzuki M, Kobayashi H, Tanaka Y, Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin. Int J Cancer 2003;104:289-302
   PubMed Web of Science ®Google Scholar
• Yoshioka I, Tsuchiya Y, Aozuka Y, Urinary trypsin inhibitor suppresses surgical stress-facilitated lung metastasis of murine colon 26-L5 carcinoma cells. Anticancer Res 2005;25:815-20
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Suzuki M, Kanayama N, Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. Eur J Biochem 2002;269:3945-57
   PubMedGoogle Scholar
• Kobayashi H, Suzuki M, Hirashima Y, Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 2003;384:749-54
   PubMed Web of Science ®Google Scholar
• Kobayashi H. Suppression of urokinase expression and tumor metastasis by bikunin overexpression [mini-review]. Hum Cell 2001;14:233-6
   PubMedGoogle Scholar
• Sato H, Kajikawa S, Kuroda S, Impaired fertility in female mice lacking urinary trypsin inhibitor. Biochem Biophys Res Commun 2001;281:1154-60
   PubMed Web of Science ®Google Scholar
• Inoue K, Takano H, Shimada A, Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol 2005;67:673-80
   PubMed Web of Science ®Google Scholar
• Ito K, Mizutani A, Kira S, Effect of Ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of activated leukocytes. Injury 2005;36:387-94
   PubMed Web of Science ®Google Scholar
• Inoue K, Takano H, Yanagisawa R, Protective role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide. Exp Biol Med (Maywood) 2005;230:281-7
   PubMed Web of Science ®Google Scholar
• Inoue K, Takano H, Yanagisawa R, Antioxidative role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide. Int J Mol Med 2005;16:1029-33
   PubMed Web of Science ®Google Scholar
• Lin SD, Endo R, Sato A, Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis. J Gastroenterol Hepatol 2002;17:140-7
   PubMed Web of Science ®Google Scholar
• Lin SD, Endo R, Kuroda H, Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:327-32
   PubMed Web of Science ®Google Scholar
• Takano H, Inoue K, Shimada A, Urinary trypsin inhibitor protects against liver injury and coagulation pathway dysregulation induced by lipopolysaccharide/D-galactosamine in mice. Lab Invest 2009;89:833-9
   PubMed Web of Science ®Google Scholar
• Inoue KI, Takano H, Sato H, Protective role of urinary trypsin inhibitor in lung expression of proinflammatory cytokines accompanied by lethal liver injury in mice. Immunopharmacol Immunotoxicol 2009;31:446-50
   PubMed Web of Science ®Google Scholar
• Nobuoka T, Mizuguchi T, Oshima H, Impaired liver regeneration with humoral and genetic disturbances in urinary trypsin inhibitor-deficient mice. Liver Int 2009;29:979-87
   PubMed Web of Science ®Google Scholar